O	0	4	Late
O	5	15	toxicities
O	16	19	and
O	20	28	outcomes
O	29	31	of
B-intervention	32	40	adjuvant
I-intervention	41	53	radiotherapy
I-intervention	54	62	combined
I-intervention	63	67	with
I-intervention	68	78	concurrent
I-intervention	79	90	bevacizumab
O	91	93	in
O	94	102	patients
O	103	107	with
O	108	114	triple
O	114	115	-
O	115	123	negative
O	124	127	non
O	127	128	-
O	128	138	metastatic
O	139	145	breast
O	146	152	cancer
O	152	153	.

O	154	156	To
O	157	165	evaluate
O	166	169	the
O	170	176	safety
O	177	179	of
O	180	183	the
O	184	194	concurrent
O	195	206	combination
O	207	209	of
O	210	221	bevacizumab
O	222	226	with
O	227	235	adjuvant
O	236	248	radiotherapy
O	249	250	(
O	250	251	B
O	251	252	-
O	252	254	RT
O	254	255	)
O	256	258	in
O	259	265	breast
O	266	272	cancer
O	273	274	(
O	274	276	BC
O	276	277	)
O	277	278	.

O	279	290	Multicentre
O	290	291	,
O	292	303	prospective
O	304	309	study
O	309	310	,
O	311	313	of
O	314	317	the
O	318	326	toxicity
O	327	329	of
O	330	338	adjuvant
O	339	351	radiotherapy
O	352	353	(
O	353	355	RT
O	355	356	)
O	357	362	alone
O	363	365	or
O	366	367	B
O	367	368	-
O	368	370	RT
O	371	373	in
O	374	382	patients
O	383	387	with
O	388	391	non
O	391	392	-
O	392	402	metastatic
O	403	405	BC
O	406	414	enrolled
O	415	417	in
O	418	428	randomized
O	429	434	Phase
O	435	436	3
O	437	445	BEATRICE
O	446	451	trial
O	451	452	.

O	453	458	Early
O	459	462	and
O	463	467	late
O	468	478	toxicities
O	479	483	were
O	484	492	assessed
O	493	495	by
O	496	499	the
O	500	506	Common
O	507	518	Terminology
O	519	527	Criteria
O	528	531	for
O	532	539	Adverse
O	540	546	Events
O	547	548	v
O	548	549	.
O	549	550	3
O	550	551	.
O	551	552	0
O	553	559	during
O	560	563	and
O	564	566	12
O	567	573	months
O	574	579	after
O	580	583	the
O	584	594	completion
O	595	597	of
O	598	600	RT
O	600	601	.

O	602	606	From
O	607	611	2007
O	612	614	to
O	615	619	2012
O	619	620	,
B-intervention-participants	621	623	39
O	624	631	females
O	632	640	received
O	641	649	adjuvant
O	650	651	B
O	651	652	-
O	652	654	RT
O	655	658	and
B-control-participants	659	661	45
O	662	670	received
B-control	671	679	adjuvant
I-control	680	682	RT
I-control	683	688	alone
O	688	689	.

O	690	696	Median
O	697	703	follow
O	703	704	-
O	704	706	up
O	707	710	was
O	711	713	21
O	713	714	.
O	714	715	5
O	716	722	months
O	722	723	.

B-eligibility	724	727	All
I-eligibility	728	736	patients
I-eligibility	737	740	had
I-eligibility	741	747	triple
I-eligibility	747	748	-
I-eligibility	748	756	negative
I-eligibility	757	760	non
I-eligibility	760	761	-
I-eligibility	761	771	metastatic
I-eligibility	772	774	BC
I-eligibility	775	778	and
I-eligibility	779	787	received
I-eligibility	788	796	adjuvant
I-eligibility	797	809	chemotherapy
I-eligibility	810	818	followed
I-eligibility	819	821	by
I-eligibility	822	824	RT
O	824	825	.

O	826	828	90
O	828	829	%
O	830	832	of
O	833	836	the
O	837	839	39
O	840	847	females
O	848	855	treated
O	856	858	by
O	859	869	concurrent
O	870	871	B
O	871	872	-
O	872	874	RT
O	875	883	received
O	884	889	whole
O	890	896	breast
O	897	908	irradiation
O	909	910	(
O	910	913	WBI
O	913	914	)
O	915	919	with
O	920	921	a
O	922	927	boost
O	928	931	and
O	932	933	4
O	934	935	(
O	935	937	10
O	937	938	%
O	938	939	)
O	940	948	received
O	949	953	post
O	953	954	-
O	954	964	mastectomy
O	965	967	RT
O	967	968	.

O	969	974	Lymph
O	975	979	node
O	980	982	RT
O	983	986	was
O	987	996	delivered
O	997	999	in
O	1000	1002	49
O	1002	1003	%
O	1004	1006	of
O	1007	1010	the
O	1011	1018	females
O	1019	1023	with
O	1024	1032	internal
O	1033	1040	mammary
O	1041	1046	chain
O	1047	1058	irradiation
O	1058	1059	.

O	1060	1063	The
O	1064	1068	mean
O	1069	1077	duration
O	1078	1080	of
O	1081	1092	bevacizumab
O	1093	1096	was
O	1097	1099	11
O	1099	1100	.
O	1100	1101	7
O	1102	1108	months
O	1108	1109	.

O	1110	1112	38
O	1113	1114	(
O	1114	1116	84
O	1116	1117	%
O	1117	1118	)
O	1119	1126	females
O	1127	1134	treated
O	1135	1137	by
O	1138	1140	RT
O	1141	1146	alone
O	1147	1155	received
O	1156	1159	WBI
O	1160	1164	with
O	1165	1166	a
O	1167	1172	boost
O	1173	1176	and
O	1177	1179	16
O	1179	1180	%
O	1181	1183	of
O	1184	1187	the
O	1188	1195	females
O	1196	1204	received
O	1205	1209	post
O	1209	1210	-
O	1210	1220	mastectomy
O	1221	1223	RT
O	1223	1224	.

O	1225	1230	Lymph
O	1231	1235	node
O	1236	1238	RT
O	1239	1242	was
O	1243	1252	delivered
O	1253	1255	in
O	1256	1258	47
O	1258	1259	%
O	1260	1262	of
O	1263	1266	the
O	1267	1274	females
O	1275	1279	with
O	1280	1288	internal
O	1289	1296	mammary
O	1297	1302	chain
O	1303	1305	RT
O	1306	1308	in
O	1309	1311	31
O	1311	1312	%
O	1312	1313	.

B-outcome	1314	1319	Grade
I-outcome	1320	1321	3
I-outcome	1322	1327	acute
I-outcome	1328	1338	dermatitis
O	1339	1342	was
O	1343	1351	observed
O	1352	1354	in
B-iv-bin-percent	1355	1356	9
I-iv-bin-percent	1356	1357	%
O	1358	1360	of
O	1361	1369	patients
O	1370	1379	receiving
O	1380	1381	B
O	1381	1382	-
O	1382	1384	RT
O	1385	1388	and
B-cv-bin-percent	1389	1390	5
I-cv-bin-percent	1390	1391	%
O	1392	1394	of
O	1395	1403	patients
O	1404	1413	receiving
O	1414	1416	RT
O	1417	1422	alone
O	1423	1427	with
O	1428	1430	no
O	1431	1442	significant
O	1443	1453	difference
O	1453	1454	.

O	1455	1456	1
O	1457	1461	year
O	1462	1467	after
O	1468	1471	the
O	1472	1482	completion
O	1483	1485	of
O	1486	1488	RT
O	1488	1489	,
O	1490	1493	the
O	1494	1498	most
O	1499	1505	common
O	1506	1510	late
O	1511	1516	grade
O	1517	1518	1
O	1518	1519	-
O	1519	1520	2
O	1521	1531	toxicities
O	1532	1534	in
O	1535	1538	the
O	1539	1540	B
O	1540	1541	-
O	1541	1543	RT
O	1544	1549	group
O	1550	1554	were
B-outcome	1555	1559	pain
O	1560	1561	(
B-iv-bin-percent	1561	1563	18
I-iv-bin-percent	1563	1564	%
O	1564	1565	)
O	1565	1566	,
B-outcome	1567	1575	fibrosis
O	1576	1577	(
B-iv-bin-percent	1577	1578	8
I-iv-bin-percent	1578	1579	%
I-iv-bin-percent	1579	1580	)
O	1581	1584	and
B-outcome	1585	1599	telangiectasia
O	1600	1601	(
B-iv-bin-percent	1601	1602	5
I-iv-bin-percent	1602	1603	%
O	1603	1604	)
O	1604	1605	.

O	1606	1609	The
O	1610	1620	concurrent
O	1621	1632	bevacizumab
O	1633	1637	with
O	1638	1650	locoregional
O	1651	1653	RT
O	1654	1656	is
O	1657	1667	associated
O	1668	1672	with
O	1673	1683	acceptable
O	1684	1689	early
O	1690	1693	and
O	1694	1698	late
O	1699	1700	1
O	1700	1701	-
O	1701	1705	year
O	1706	1716	toxicities
O	1717	1719	in
O	1720	1728	patients
O	1729	1733	with
O	1734	1736	BC
O	1736	1737	.

O	1738	1741	The
O	1742	1749	largest
O	1750	1756	series
O	1757	1759	of
O	1760	1764	this
O	1765	1776	association
O	1776	1777	.
